Filing Details
- Accession Number:
- 0001140361-14-025828
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-06-16 19:48:14
- Reporting Period:
- 2014-06-12
- Filing Date:
- 2014-06-16
- Accepted Time:
- 2014-06-16 19:48:14
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1228627 | Rexahn Pharmaceuticals Inc. | RNN | Pharmaceutical Preparations (2834) | 113516358 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1316420 | Ho Chang Ahn | C/O Rexahn Pharmaceuticals, Inc. 15245 Shady Grove Road, Suite 455 Rockville MD 20850 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2014-06-12 | 136,193 | $0.80 | 6,950,117 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2014-06-12 | 136,193 | $0.99 | 6,813,924 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to purchase) | Disposition | 2014-06-12 | 136,193 | $0.00 | 136,193 | $0.80 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 863,807 | 2015-01-20 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 500,000 | Indirect | By spouse |
Footnotes
- The price of $0.9871 per share represents a weighted average of sales prices ranging from $0.9831 to $1.005 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- The reporting person disclaims beneficial ownership of the shares held by his spouse, and this report should not be deemed an admission that the reporting person is the beneficial owner of his spouse's shares for purposes of Section 16 or any other purpose.
- Options vested and became exercisable based on the following schedule: 300,000 on January 20, 2006, 300,000 on January 20, 2007, and 400,000 on January 20, 2008.
Billionaire Hedge Funds
